Revelation Biosciences, Inc. financial data

Symbol
REVB, REVBW on Nasdaq
Industry
Pharmaceutical Preparations
Location
4660 Lajolla Village Drive, Suite 100, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Petra Acquisition Inc. (to 1/11/2022)
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 176 % -26%
Debt-to-equity 130 % +80.8%
Return On Assets -135 % -2180%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.29M shares -31.8%
Common Stock, Shares, Outstanding 4.29M shares -31.8%
Entity Public Float 7.31M USD -45%
Common Stock, Value, Issued 4.29K USD -31.8%
Weighted Average Number of Shares Outstanding, Basic 2.68M shares +913%
Weighted Average Number of Shares Outstanding, Diluted 2.68M shares +913%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4M USD +16.9%
General and Administrative Expense 4.54M USD +10.2%
Operating Income (Loss) -8.55M USD -13.2%
Nonoperating Income (Expense) -6.97M USD -183%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -15.5M USD -1873%
Earnings Per Share, Basic -38.7 USD/shares +60.3%
Earnings Per Share, Diluted -30.3 USD/shares +71.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.54M USD -53.3%
Assets, Current 6.66M USD -52.9%
Property, Plant and Equipment, Net 81.2K USD +13.9%
Assets 6.74M USD -52.6%
Accounts Payable, Current 3.13M USD +149%
Accrued Liabilities, Current 934K USD -8.58%
Liabilities, Current 4.07M USD -24.7%
Liabilities 4.07M USD -24.7%
Retained Earnings (Accumulated Deficit) -38.8M USD -66.7%
Stockholders' Equity Attributable to Parent 2.67M USD -69.7%
Liabilities and Equity 6.74M USD -52.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.84M USD -80.2%
Net Cash Provided by (Used in) Financing Activities 5.42M USD -61.4%
Net Cash Provided by (Used in) Investing Activities -19.2K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 4.29M shares -31.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.54M USD -53.3%
Deferred Tax Assets, Valuation Allowance 10.5M USD +23.6%
Deferred Tax Assets, Gross 10.5M USD +23.6%
Depreciation 27K USD +7.65%
Payments to Acquire Property, Plant, and Equipment 19.2K USD
Property, Plant and Equipment, Gross 169K USD +27.9%
Deferred Tax Assets, Operating Loss Carryforwards 7.28M USD +32.1%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 41.4M USD +29.2%
Share-based Payment Arrangement, Expense 128K USD -17.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%